Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
Medicinova, Inc. (NASDAQ: MNOV), headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on acquiring and developing promising small-molecule therapeutics to treat diseases with unmet medical needs. Specializing in therapies for neurological disorders and fibrotic diseases, Medicinova has a strategic emphasis on the U.S. market.
Medicinova’s robust product portfolio includes several innovative drugs in late-stage clinical development. These include MN-001 (tipelukast) and MN-166 (ibudilast), both of which boast multiple mechanisms of action and strong safety profiles. MN-166 (ibudilast) is in Phase 3 clinical trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). It is also being evaluated in Phase 2 trials for Long COVID, substance dependence, and other neurodegenerative diseases.
The company recently received a series of new patents, significantly extending its intellectual property protection. One such patent covers the use of MN-166 for treating macular injury and decreasing macular volume loss associated with progressive multiple sclerosis. Another patent covers the formulation of MN-166 in extended-release oral forms, which is expected to improve patient compliance and reduce side effects.
Medicinova has demonstrated the potential of MN-166 in ophthalmic neurodegenerative diseases, supported by positive data from various animal model studies and the SPRINT-MS Phase 2b trial. Additionally, MN-166 is under investigation for its efficacy in treating glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder.
Alongside its development efforts, Medicinova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. This financial support underscores the promise and potential of its therapies to address critical medical needs.
For more information or investor inquiries, please contact Geoff O'Brien, Vice President at info@medicinova.com.
MediciNova, Inc. (NASDAQ: MNOV) announced the presentation of its ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND, held virtually from December 7-10, 2021. Dr. Malath Makhay detailed the trial's objectives, design, and recent adaptations to enhance patient participation. The trial aims to enroll 230 patients across 30 sites, with the primary endpoint being the change in ALSFRS-R score at 12 months. CEO Dr. Yuichi Iwaki highlighted the trial's importance and the addition of new recruitment sites.
MediciNova (NASDAQ:MNOV) has announced promising results from a study presented by Dr. Justin Lathia at the Society for Neuro-Oncology's annual meeting regarding the efficacy of MN-166 (ibudilast) in combination with PD-1 inhibitors for treating glioblastoma (GBM). The study demonstrated a median survival increase from 28 days with PD-1 alone to 66 days when combined with MN-166, a significant finding (p<0.001). MediciNova aims to progress to clinical trials based on these encouraging outcomes, underscoring the potential of MN-166 to enhance GBM treatment.
MediciNova, Inc. (NASDAQ:MNOV) announced a study by Dr. Masatsune Ogura, revealing MN-001 (tipelukast) reduces triglyceride (TG) synthesis in liver cells. Presented at The Liver Meeting 2021, findings indicate that MN-001 inhibits TG synthesis by suppressing CD36 expression, a fatty acid transporter, in HepG2 cells. Compared to untreated cells, TG synthesis increased significantly with arachidonic acid and LXR agonist T0901317. MN-001 shows potential in addressing nonalcoholic steatohepatitis (NASH) by improving lipid metabolism.
MediciNova, Inc. (NASDAQ:MNOV) announced promising findings regarding MN-166 (ibudilast) in a uveal melanoma model presented by Dr. Grazia Ambrosini at the 10th Annual CURE OM Global Science Meeting. The study indicated that MN-166 significantly reduced migration of UM cells and prevented metastasis in mice. Key mechanisms involve macrophage migration inhibitory factor (MIF). This data positions MN-166 as a potential preventive treatment for uveal melanoma, addressing critical unmet needs in this area. The company aims to proceed to clinical trials to evaluate MN-166's efficacy in combating cancer metastasis.
MediciNova, Inc. (NASDAQ:MNOV) announced that Dr. Justin Lathia from the Cleveland Clinic will present new findings on MN-166 (ibudilast) in a glioblastoma animal model at the 26th Annual Meeting of the Society for Neuro-Oncology in Boston, scheduled for November 18-21, 2021. The presentation will occur on November 20, focusing on the role of myeloid cells in glioblastoma. MN-166 is a compound in late-stage clinical development for various neurodegenerative diseases and conditions, showcasing its potential in a range of therapeutic areas.
MediciNova, Inc. (NASDAQ: MNOV) announced the selection of an abstract showcasing MN-001 (tipelukast) at the 19th International Symposium on Atherosclerosis (ISA2021) from October 24-27, 2021. The study reveals that MN-001 inhibits arachidonic acid uptake, thereby reducing triglyceride (TG) synthesis in hepatocytes by down-regulating CD36 expression. Dr. Masatsune Ogura will present the findings online post-conference. Previously, MN-001 demonstrated significant TG reduction in clinical trials, showing potential for treating conditions like NASH. MediciNova continues its focus on developing therapies for inflammatory and fibrotic diseases.
MediciNova, a biopharmaceutical company (NASDAQ:MNOV), will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021. CEO Yuichi Iwaki and VP Geoffrey O'Brien will hold one-on-one meetings, with investor requests facilitated through Morgan Stanley. MediciNova develops therapies for inflammatory and neurodegenerative diseases, with its lead asset MN-166 in Phase 3 trials for ALS and DCM. The company has a diverse pipeline, with additional clinical programs underway for multiple conditions.
MediciNova, Inc. (NASDAQ: MNOV) announced that an abstract titled Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD will be presented at The Liver Meeting® 2021, occurring from November 12-15, 2021. Dr. Masatsune Ogura from Chiba University will present findings on MN-001's (tipelukast) effects on lipid metabolism, notably its ability to suppress triglyceride synthesis and lower serum triglyceride levels. MN-001 aims to treat NASH/NAFLD through novel anti-inflammatory and anti-fibrotic mechanisms, with additional potential applications in various fibrotic diseases.
MediciNova, a biopharmaceutical company (NASDAQ:MNOV), announced the acceptance of an abstract regarding its Phase 2b/3 trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND, set for December 7-10, 2021. The presentation will be led by Chief Medical Officer Kazuko Matsuda. The COMBAT-ALS trial aims to assess efficacy and safety with 230 participants across the U.S., Canada, and Europe. MN-166 is also in development for other neurodegenerative diseases and conditions like glioblastoma and ARDS.
MediciNova, Inc. (NASDAQ: MNOV) reported significant advancements in its drug development pipeline in its Q2 2021 update. The company initiated preclinical studies for MN-166 (ibudilast) targeting chlorine gas-induced lung disease, with positive Phase 2 results in alcohol use disorder published in Nature Journal, reinforcing MN-166's safety and potential. Ongoing patient enrollment continues for the Phase 3 trial of MN-166 in amyotrophic lateral sclerosis (ALS). Financially, MediciNova reported a cash balance of $77.8 million, projected to support operations through 2022.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
What is Medicinova, Inc.?
What are the key areas of focus for Medicinova?
What are the main products in Medicinova's pipeline?
What is MN-166 (ibudilast)?
What recent achievements has Medicinova made?
What financial backing does Medicinova have?
How does MN-166 (ibudilast) work?
What is the significance of Medicinova's new patents?
Where is Medicinova headquartered?
How can investors contact Medicinova?
